Before you read: what science sees, and what it can't

This area gathers what formal research has documented about iboga and ibogaine: published studies, clinical trials and reviews. It is one valuable way of knowing this medicine, and not the only one. Wanting to understand before deciding is a good place to start, and you are welcome here, with all your questions.

What science can see

Measurement is good at what can be counted and repeated. Research has described doses, what ibogaine does to the rhythm of the heart and which medicines interact with it (Koenig & Hilber, 2015), and the many receptor systems it acts on, in ways still not fully understood (Oña et al., 2023). It is the knowledge that weighs most in a person's care: who should not take ibogaine, what to stop beforehand, what to watch in the body.

What it struggles to see

Most medicines are tested one target at a time, against a placebo, with neither the person nor the researcher knowing who received what. Iboga resists that design. Ibogaine has no single target, and its experience is so strong that almost everyone knows whether they took it. What happens is also shaped by what a trial tries to hold still: the setting, what a person expects, the people around them and the meaning the experience takes on. And it is often one treatment followed by a long integration, which a study can follow only in part.

That something cannot be measured does not mean it does not exist. Nor does it mean it carries no risk.

Where iboga comes from

Long before any laboratory, several peoples of Gabon and the Congo Basin had used Tabernanthe iboga for generations. It is best known for its place in the Bwiti tradition, which works with the whole plant in initiation and healing ceremonies, in community (Fernandez, 1982; MAPS, 2026, p. 23). Initiation, with a large amount of the root bark, is taken once or twice in a lifetime, with others already initiated at the person's side the whole time; regular services use much smaller amounts (Bastiaans, 2004; MAPS, 2026, p. 98). This is knowledge of another kind than a trial's, and neither one replaces the other.

Western science came late. Ibogaine, one of the alkaloids in the plant's root, was isolated in France in 1901 (Dybowski & Landrin, 1901). In 1962, in New York, Howard Lotsof, then dependent on heroin, took it and reported that the withdrawal and the craving did not come, an account that opened its use in addiction (Alper, Beal & Kaplan, 2001). "The person that discovered the addiction-interruption qualities of ibogaine, Howard Lotsof, was a friend of mine since 1968," says Barry Rossinoff, IbogaQuest's founder.

A few years later, in Chile, the psychiatrist Claudio Naranjo worked with ibogaine as an aid to psychotherapy and presented that work in 1966 (Naranjo, 1973/2013, p. 155), an early bridge between science and the inner journey. For him, psychotherapy and mysticism, "rightly understood," are "but different stages in a single journey of the soul" (p. 14).

Today the country where iboga grows is also deciding on what terms it enters the world. In 2026 Gabon drafted a decree naming iboga and ibogaine "strategic national heritage," to protect the plant and share its benefits with the country and the communities that have long looked after it. It is still a draft, and MAPS notes that scientific and commercial expansion is moving faster than that fair sharing (MAPS, 2026, pp. 25–26).

How to read what follows

Studies describe groups, not you: your body, your history and your medicines are your own. "Not studied" does not mean "without risk," and it does not mean "harmful": it means not yet known. A preprint is early work that other scientists have not yet reviewed. And ibogaine is not for everyone.

Science has described the risks precisely, and they deserve to be told with their context. Ibogaine can disturb the rhythm of the heart and can interact dangerously with some medications, and the medical literature records serious complications, including deaths (Koenig & Hilber, 2015). We know there is a risk, and we take it seriously. Most of those deaths involved something a medical evaluation is designed to find, such as heart disease, other drugs in the body, liver disease or withdrawal from alcohol or sedatives (Alper et al., 2012; MAPS, 2026). In the largest recent survey, still a preprint, the deaths occurred during treatment for opioid dependence, and no deaths were reported among people treated for other reasons (Arns et al., 2026). Evaluation lowers that risk; it does not remove it. That is why no one receives treatment with us without a full medical evaluation, why some people do a detox first, and why, on every medicine day, our team is on site and ready to respond.

Read the rest of this area as the part of knowledge about iboga that is documented today. If something leaves you with questions about your own case, write to our medical team.

References

• Alper, K. R., Beal, D., & Kaplan, C. D. (2001). A contemporary history of ibogaine in the United States and Europe. The Alkaloids: Chemistry and Biology, 56, 249–281. PMID 11705112.
• Alper, K. R., Stajić, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412. https://doi.org/10.1111/j.1556-4029.2011.02008.x
• Arns, M., Shinozuka, K., & Barsuglia, J. (2026). Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: A multisite analysis of 19,071 patients and updated systematic review of fatalities. Research Square (preprint, in review; not peer reviewed). https://doi.org/10.21203/rs.3.rs-9966269/v1
• Bastiaans, E. (2004). Life after ibogaine: An exploratory study of the long-term effects of ibogaine treatment on drug addicts (Science internship report, Faculty of Medicine, Vrije Universiteit Amsterdam; not peer reviewed).
• Dybowski, J., & Landrin, E. (1901). Sur l'iboga, sur ses propriétés excitantes, sa composition et sur l'alcaloïde nouveau qu'il renferme, l'ibogaïne. Comptes rendus de l'Académie des sciences, 133.
• Fernandez, J. W. (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press.
• Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules, 20(2), 2208–2228. https://doi.org/10.3390/molecules20022208
• MAPS. (2026). Ibogaine Investigator's Brochure (July 2026 IB), Version 1 (version date 1 June 2026). Lead author B. Pluimer. https://maps.org/2026/06/30/ibogaine-investigators-brochure/
• Naranjo, C. (2013). The Healing Journey: Pioneering Approaches to Psychedelic Therapy (2nd ed.; preface by S. Grof). Santa Cruz, CA: MAPS. (Original work published 1973 by Pantheon.) Ch. V, "Ibogaine: Fantasy and Reality," pp. 155–201.
• Oña, G., Reverte, I., Rossi, G. N., dos Santos, R. G., Hallak, J. E. C., Colomina, M. T., & Bouso, J. C. (2023). Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of Psychopharmacology, 37(12), 1190–1200. PMID 37937505.
• Rossinoff, B. Interview with IbogaQuest (unpublished; quoted with permission).